Wageningen University
Wageningen, Gelderland, 6708WD, Netherlands
Location status: Recruiting
Location contact
Marlou Dirks, PhD
CONTACT
Marlou Dirks, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07062562
The goal of this clinical trial is to examine the effect of whole-body electrostimulation with protein intake on muscle protein synthesis, muscle mass and function during bed rest in healthy young adults (18-35 years). The main questions to answer are:
* Does whole-body NMES followed by protein intake improve muscle protein synthesis rates during 3 days of bed rest? * Does repeated NMES sessions offer protective effects on muscle mass and function during extended periods of inactivity?
Researchers will compare sham electrical electrostimulation, electrical stimulation and electrical stimulation + protein groups to see if whole-body electrostimulation combined with protein intake offers the greatest improvement in muscle protein metabolism and muscle preservation.
Participants will:
* Undergo 3 days of bed rest while receiving one of the following interventions:
* Sham-NMES followed by standard nutrition (CON) * Whole-body NMES followed by standard nutrition(NMES) * Whole-body NMES followed by a bolus of 20g protein (NMES+PRO) * Receive heavy water (D2O) to assess body water turnover. * Undergo leg extension exercises to assess muscle function. * Have quadriceps muscle thickness measured via ultrasound. * Provide saliva samples for analysis. * Have calf circumference measured to monitor changes in muscle mass.
Interested in participating?
Request Info18 year–35 year
All sexes
Interventional
Not applicable
Wageningen, Gelderland, 6708WD, Netherlands
Location status: Recruiting
Marlou Dirks, PhD
CONTACT
Marlou Dirks, PhD
PRINCIPAL_INVESTIGATOR
Patients admitted to the hospital often experience prolonged bed rest, which can lead to rapid muscle loss and weakness. In the intensive care unit (ICU), this condition, known as ICU-acquired weakness (ICU-AW), affects up to 50% of patients and can lead to longer mechanical ventilation times, increased morbidity, and a reduced quality of life after hospital discharge. One of the key reasons for muscle loss during bed rest is an impaired response to dietary protein, which normally helps maintain muscle mass.
Neuromuscular electrical stimulation (NMES) is a method that uses small electrical currents to stimulate muscle contractions, potentially counteracting muscle loss during periods of inactivity. Previous research has shown that NMES applied to the quadriceps muscles can reduce muscle loss in sedated patients and improve muscle protein synthesis in individuals with type 2 diabetes. However, the effects of whole-body NMES in combination with timed protein intake on muscle protein metabolism during bed rest are still unknown.
This study aims to investigate the impact of both a single session and repeated sessions of whole-body NMES, with or without subsequent protein intake, on muscle protein synthesis rates, muscle mass, and function during 3 days of bed rest in healthy young adults.
Study Design:
This is a randomized, placebo-controlled clinical trial with three parallel groups. Participants will be randomly assigned to one of the following groups:
Study Procedures:
Participants will be healthy adults (18-35 years, male and female) and will undergo the following procedures:
This study will provide critical insights into how NMES and protein intake can help counteract muscle loss and weakness during hospitalization and may contribute to the development of more effective rehabilitation strategies for ICU and bedridden patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
≥90 mmHg diastolic)
arthritis, spasticity/rigidity, all neurological disorders and paralysis)
A placebo treatment in which no actual electrical stimulation is delivered, serving as a control for the active NMES.
Active neuromuscular electrical stimulation applied to the entire body to induce muscle contractions through small electric currents.
A bolus dose of 20 grams of protein provided after the NMES intervention to assess the combined effect of muscle stimulation and protein intake on muscle protein metabolism.
Provision of a normal Western standardized diet.
Time frame: Habitual MPS (Day -2 to Day 0), Acute effect of NMES (+protein bolus) (0 hours to 5 hours on Day 0), Bedrest MPS (Day 0 to Day 3),
A measure of muscle protein synthesis between two given time points.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Assessed using ultrasound, this measures changes in muscle size, indicating muscle loss or preservation during bed rest and NMES intervention.
Time frame: Day 0 and Day 3.
Evaluates muscle mass to determine overall changes.
Time frame: Time Frame: Day 0 and Day 3.
Evaluates fat distribution to determine overall changes.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Assessed via a leg dynamometer.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Assessed via a leg dynamometer.
Time frame: Between Day -21 and Day -5, Day 0, Day 3, Day 6, Week 6
Assessed via a hand dynamometer.
Time frame: Day 0 to Day 3
The balance between nitrogen intake (from dietary protein) and nitrogen loss (through urine and other excretions)
Contact information is provided by the study sponsor or research team.
Wageningen University
Other
The Effect of Repeated Sessions of Whole-body Neuromuscular Electrical Stimulation (NMES), With or Without Subsequent Intake of a Protein Bolus, on Muscle Protein Synthesis in Healthy, Young Volunteers During 3 Days of Bed Rest
Acronym: SPRINT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07643558
Atrophy, Cancer
Erlangen, Bavaria, Germany
View Trial DetailsNCT06697470
Atrophy, Critical Illness
Boussu, Hainaut, Belgium
View Trial DetailsNCT07607236
Atrophy, Frailty
Chengdu, Sichuan, China
View Trial DetailsNCT06104527
Atrophy, Critical Illness
Maastricht, Limburg, Netherlands
View Trial Details